Lisa Delfini - 13 Feb 2023 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role: Chief Financial Officer
Signature: /s/ Christopher Galletta, attorney-in-fact
Issuer symbol: TRVI
Transactions as of: 13 Feb 2023
Net transactions value: -$6,709
Form type: 4
Filing time: 15 Feb 2023, 15:01:34 UTC
Previous filing: 15 Feb 2022
Next filing: 16 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRVI	Common Stock	Options Exercise	$14,052	+27,500	+638%	$0.5110^*	31,812	13 Feb 2023	Direct	F1, F2
transaction	TRVI	Common Stock	Sale	$20,761	-8,474	-27%	$2.45	23,338	13 Feb 2023	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRVI	Stock Option (right to buy)	Options Exercise	$0	-27,500	-25%	$0.000000	82,500	13 Feb 2023	Common Stock	27,500	$0.5110	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan.
F2	This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on February 13, 2023.
F3	Includes 4,312 shares purchased through the Issuer's employee stock purchase plan.
F4	This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.